HOME > BUSINESS
BUSINESS
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- No Major Drug Supply Disruption after Typhoon Hagibis
October 16, 2019
- Sakigake-Designated Radiation Therapy Agent Filed in Japan
October 16, 2019
- OrphanPacific to Take Over Marketing Authorization for MSD’s Diazoxide
October 16, 2019
- Sanofi, Kaken to Wind Up Clexane Partnership
October 16, 2019
- Eyes Turn to SGLT2 Inhibitors after Entresto’s Narrow Miss in HFpEF
October 16, 2019
- AZ, Sanofi Kick Off Japan PIII for RSV Prevention
October 15, 2019
- MSD Seeking to Trim 250 Jobs in Japan
October 15, 2019
- Japan Ethical Drug Market Forecast at 8.9 Trillion Yen in 2026: Fuji Keizai
October 15, 2019
- Shionogi Signs New Mycobacterial Deal with Hsiri
October 15, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- All Eyes on Performance of Top-2 Anti-Flu Drugs Xofluza, Inavir as Flu Seasons Approaches
October 11, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- AZ, Keio Univ. Pair Up to Create Real World Evidence in Healthcare
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Mitsubishi Tanabe Gains Japan, Asian Rights for Viela Bio's Inebilizumab
October 10, 2019
- Meiji to Strengthen Contract Manufacturing, Aims to Produce 3 Billion Tablets Annually for Japan Market
October 10, 2019
- Bayer, RIKEN Innovation Tie Up on Drug Discovery
October 9, 2019
- AbbVie Japan Set to Join Oncology Fray with CLL Drug, Accelerating FIH Trial Entry
October 9, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
